| JPM THEMATICS-GENETIC THERAPIES C (DIST) USD | RVI BIOTECNOLOGÍA | 69,657781 | 24/09/2026 | 22,33% | 33,01% | ** |
| JPM THEMATICS-GENETIC THERAPIES D (ACC) EUR (HEDGED) | RVI BIOTECNOLOGÍA | 95,390000 | 24/09/2026 | 16,87% | 30,89% | ** |
| JPM THEMATICS-GENETIC THERAPIES D (ACC) USD | RVI BIOTECNOLOGÍA | 77,918536 | 24/09/2026 | 21,30% | 28,44% | ** |
| JPM THEMATICS-GENETIC THERAPIES I2 (ACC) EUR (HEDGED) | RVI BIOTECNOLOGÍA | 119,160000 | 24/09/2026 | 18,23% | 37,14% | ** |
| JPM THEMATICS-GENETIC THERAPIES I2 (ACC) USD | RVI BIOTECNOLOGÍA | 88,246679 | 24/09/2026 | 22,72% | 34,72% | ** |
| JPM THEMATICS-GENETIC THERAPIES I (ACC) EUR | RVI BIOTECNOLOGÍA | 86,350000 | 24/09/2026 | 22,34% | 34,48% | ** |
| JPM THEMATICS-GENETIC THERAPIES I (ACC) EUR (HEDGED) | RVI BIOTECNOLOGÍA | 83,740000 | 24/09/2026 | 18,13% | 36,74% | ** |
| JPM TOTAL EMERGING MARKETS INCOME A (ACC) EUR | MIXTO AGRESIVO GLOBAL | 156,400000 | 24/09/2026 | 16,83% | 44,72% | ***** |
| JPM TOTAL EMERGING MARKETS INCOME A (ACC) USD | MIXTO AGRESIVO GLOBAL | 156,382511 | 24/09/2026 | 17,11% | 44,59% | ***** |
| JPM TOTAL EMERGING MARKETS INCOME A (DIST) EUR | MIXTO AGRESIVO GLOBAL | 110,130000 | 24/09/2026 | 14,05% | 33,22% | ** |